Anatoly Dritschilo

Summary

Affiliation: Georgetown University
Country: USA

Publications

  1. ncbi Phase I study of liposome-encapsulated c-raf antisense oligodeoxyribonucleotide infusion in combination with radiation therapy in patients with advanced malignancies
    Anatoly Dritschilo
    Department of Radiation Medicine, Lombardi Comprehensive Cancer Center, Georgetown University, Washington, District of Columbia 20007
    Clin Cancer Res 12:1251-9. 2006
  2. ncbi Enhanced therapeutic effects of doxorubicin and paclitaxel in combination with liposome-entrapped ends-modified raf antisense oligonucleotide against human prostate, lung and breast tumor models
    Rajshree R Mewani
    Department of Radiation Medicine, Georgetown University Medical Center, NW, Washington, DC 20057, USA
    Int J Oncol 24:1181-8. 2004
  3. ncbi BRCC2, a novel BH3-like domain-containing protein, induces apoptosis in a caspase-dependent manner
    Constantinos G Broustas
    Department of Radiation Medicine, Lombardi Cancer Center, Georgetown University, Washington, D C 20057, USA
    J Biol Chem 279:26780-8. 2004
  4. ncbi Combined transcriptional and translational targeting of EWS/FLI-1 in Ewing's sarcoma
    Silvia Mateo-Lozano
    Laboratory of Experimental Carcinogenesis, Department of Radiation Medicine, V T Lombardi Comprehensive Cancer Center, Georgetown University, Washington, District of Columbia 20057 1482, USA
    Clin Cancer Res 12:6781-90. 2006
  5. ncbi Interaction and stabilization of X-linked inhibitor of apoptosis by Raf-1 protein kinase
    Song Tian
    Department of Radiation Medicine, Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington DC 20057, USA
    Int J Oncol 29:861-7. 2006
  6. ncbi Gene expression profile by inhibiting Raf-1 protein kinase in breast cancer cells
    Rajshree R Mewani
    Department of Radiation Medicine, Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC 20057, USA
    Int J Mol Med 17:457-63. 2006
  7. ncbi Combination with liposome-entrapped, ends-modified raf antisense oligonucleotide (LErafAON) improves the anti-tumor efficacies of cisplatin, epirubicin, mitoxantrone, docetaxel and gemcitabine
    Jin Pei
    Department of Radiation Medicine, Lombardi Cancer Center, Georgetown University Medical Center, Washington, DC 20007, USA
    Anticancer Drugs 15:243-53. 2004
  8. pmc Stereotactic body radiation therapy (SBRT) for clinically localized prostate cancer: the Georgetown University experience
    Leonard N Chen
    Department of Radiation Medicine, Georgetown University Hospital, Washington, DC 20007, USA
    Radiat Oncol 8:58. 2013
  9. pmc AMP-activated protein kinase promotes human prostate cancer cell growth and survival
    Hyeon Ung Park
    Department of Radiation Medicine, Georgetown University Medical Center, Georgetown University Hospital, Lower Level, Bles Building, 3800 Reservoir Road Northwest, Washington, DC 20007, USA
    Mol Cancer Ther 8:733-41. 2009
  10. doi Functional proteomics analysis to study ATM dependent signaling in response to ionizing radiation
    Amrita K Cheema
    Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC, USA
    Radiat Res 179:674-83. 2013

Collaborators

Detail Information

Publications47

  1. ncbi Phase I study of liposome-encapsulated c-raf antisense oligodeoxyribonucleotide infusion in combination with radiation therapy in patients with advanced malignancies
    Anatoly Dritschilo
    Department of Radiation Medicine, Lombardi Comprehensive Cancer Center, Georgetown University, Washington, District of Columbia 20007
    Clin Cancer Res 12:1251-9. 2006
    ..In this dose escalation study, we evaluated the safety of combined liposomal formulation of raf antisense oligonucleotide (LErafAON) and radiation therapy in patients with advanced malignancies...
  2. ncbi Enhanced therapeutic effects of doxorubicin and paclitaxel in combination with liposome-entrapped ends-modified raf antisense oligonucleotide against human prostate, lung and breast tumor models
    Rajshree R Mewani
    Department of Radiation Medicine, Georgetown University Medical Center, NW, Washington, DC 20057, USA
    Int J Oncol 24:1181-8. 2004
    ..These preclinical observations support the use of LErafAON in combination with chemotherapeutic agents to improve the treatment of human cancers...
  3. ncbi BRCC2, a novel BH3-like domain-containing protein, induces apoptosis in a caspase-dependent manner
    Constantinos G Broustas
    Department of Radiation Medicine, Lombardi Cancer Center, Georgetown University, Washington, D C 20057, USA
    J Biol Chem 279:26780-8. 2004
    ..These findings demonstrate that BRCC2 functions as a proapoptotic molecule and suggest that BRCC2 induces a caspase-dependent mitochondrial pathway of cell death...
  4. ncbi Combined transcriptional and translational targeting of EWS/FLI-1 in Ewing's sarcoma
    Silvia Mateo-Lozano
    Laboratory of Experimental Carcinogenesis, Department of Radiation Medicine, V T Lombardi Comprehensive Cancer Center, Georgetown University, Washington, District of Columbia 20057 1482, USA
    Clin Cancer Res 12:6781-90. 2006
    ....
  5. ncbi Interaction and stabilization of X-linked inhibitor of apoptosis by Raf-1 protein kinase
    Song Tian
    Department of Radiation Medicine, Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington DC 20057, USA
    Int J Oncol 29:861-7. 2006
    ..Our studies identify XIAP as a new substrate of Raf-1 and provide potentially important insight into mechanisms underlying Raf-1 effects on cell survival...
  6. ncbi Gene expression profile by inhibiting Raf-1 protein kinase in breast cancer cells
    Rajshree R Mewani
    Department of Radiation Medicine, Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC 20057, USA
    Int J Mol Med 17:457-63. 2006
    ..Real-time PCR, Northern analysis and Western analysis confirmed the microarray findings. Our study provides insight into Raf-1 related signaling pathways and a model system to identify potential target genes...
  7. ncbi Combination with liposome-entrapped, ends-modified raf antisense oligonucleotide (LErafAON) improves the anti-tumor efficacies of cisplatin, epirubicin, mitoxantrone, docetaxel and gemcitabine
    Jin Pei
    Department of Radiation Medicine, Lombardi Cancer Center, Georgetown University Medical Center, Washington, DC 20007, USA
    Anticancer Drugs 15:243-53. 2004
    ..These data provide a proof-of-principle for the clinical use of LErafAON in combination with chemotherapy for cancer treatment...
  8. pmc Stereotactic body radiation therapy (SBRT) for clinically localized prostate cancer: the Georgetown University experience
    Leonard N Chen
    Department of Radiation Medicine, Georgetown University Hospital, Washington, DC 20007, USA
    Radiat Oncol 8:58. 2013
    ..We report our early experience using SBRT for localized prostate cancer...
  9. pmc AMP-activated protein kinase promotes human prostate cancer cell growth and survival
    Hyeon Ung Park
    Department of Radiation Medicine, Georgetown University Medical Center, Georgetown University Hospital, Lower Level, Bles Building, 3800 Reservoir Road Northwest, Washington, DC 20007, USA
    Mol Cancer Ther 8:733-41. 2009
    ..The evidence provided here is the first report that the activated AMPK pathway is involved in the growth and survival of human prostate cancer and offers novel potential targets for chemoprevention of human prostate cancer...
  10. doi Functional proteomics analysis to study ATM dependent signaling in response to ionizing radiation
    Amrita K Cheema
    Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC, USA
    Radiat Res 179:674-83. 2013
    ..These molecular networks offer a hypothesis generating function for further investigations of cellular stress responses...
  11. pmc Patient-reported urinary incontinence following stereotactic body radiation therapy (SBRT) for clinically localized prostate cancer
    Leonard N Chen
    Department of Radiation Medicine, Georgetown University Hospital, 3800 Reservoir Road, N W, Washington, DC 20007, USA
    Radiat Oncol 9:148. 2014
    ..This study sought to evaluate the incidence of UI following stereotactic body radiation therapy (SBRT) for prostate cancer...
  12. pmc Hypofractionated stereotactic body radiation therapy as monotherapy for intermediate-risk prostate cancer
    Andrew W Ju
    Department of Radiation Medicine, LL Bles Building, 3800 Reservoir Rd NW, Washington, DC 20007, USA
    Radiat Oncol 8:30. 2013
    ..We examined the dose distributions and early clinical outcomes using this modality for the treatment of intermediate-risk prostate cancer...
  13. pmc STAT3 suppresses transcription of proapoptotic genes in cancer cells with the involvement of its N-terminal domain
    Olga A Timofeeva
    Department of Oncology and Radiation Medicine, and Drug Discovery Program, Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC 20057, USA
    Proc Natl Acad Sci U S A 110:1267-72. 2013
    ..These data demonstrate a suppressive role for the STAT3 ND in the regulation of proapoptotic gene expression in cancer cells, providing further support for targeting STAT3 ND for cancer therapy...
  14. ncbi Attenuated DNA damage repair by trichostatin A through BRCA1 suppression
    Yin Zhang
    Division of Radiation Research, Department of Radiation Medicine, Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC 20057, USA
    Radiat Res 168:115-24. 2007
    ..Our data demonstrate for the first time that TSA treatment modulates the radiation-induced DNA damage repair process, in part by suppressing BRCA1 gene expression, suggesting that BRCA1 is one of molecular targets of TSA...
  15. ncbi Interstitial gene delivery in human xenograft prostate tumors using titanium metal seeds
    Mira Jung
    Department of Radiation Medicine, Division of Radiation Research, Georgetown University Medical Center, Research Building, Suite E211, Box 571482, Washington, DC 20057 1482, USA
    Mol Cancer Ther 3:655-9. 2004
    ..The expression of TNF-alpha resulted in tumor growth delay of a human prostate cancer xenograft. These results demonstrate the feasibility of applying interstitial delivery of gene expressing vectors for the treatment of human cancers...
  16. ncbi Rational design and development of radiation-sensitizing histone deacetylase inhibitors
    Mira Jung
    Department of Radiation Medicine, Georgetown University Medical Center, The Research Building, Room E202, Box 571482, 3970 Reservoir Road NW, Washington, DC 20057 1482, USA
    Chem Biodivers 2:1452-61. 2005
    ..Cell-type specificities in radiation-sensitizing properties have been observed. Mechanisms underlying specificity are under investigation...
  17. ncbi The p65 subunit of nuclear factor-kappaB is a molecular target for radiation sensitization of human squamous carcinoma cells
    Kyoung M Kim
    Department of Radiation Medicine, Division of Radiation Research, Georgetown University, Research Building, Suite E211, Box 571482, Washington, DC 20057 1482, USA
    Mol Cancer Ther 3:693-8. 2004
    ..The NH(2)-terminal region of p65 is thus a potential molecular target for disruption of NF-kappaB activation and sensitization of tumors to radiotherapy...
  18. doi Preclinical studies of YK-4-272, an inhibitor of class II histone deacetylases by disruption of nucleocytoplasmic shuttling
    Hye Sik Kong
    Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, 3970 Reservoir Road, Washington, District of Colombia 20057, USA
    Pharm Res 29:3373-83. 2012
    ..Pre-clinical investigations of YK-4-272 bioavailability, pharmacokinetics, in vivo toxicity and tumor growth inhibition were performed to determine its potential as an HDAC shuttling disruptor for use in clinical applications...
  19. pmc Binding kinetics and activity of human poly(ADP-ribose) polymerase-1 on oligo-deoxyribonucleotide substrates
    Timothy J Jorgensen
    Departments of Radiation Medicine, Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC 20057, USA
    J Mol Recognit 22:446-52. 2009
    ....
  20. pmc Low incidence of new biochemical and clinical hypogonadism following hypofractionated stereotactic body radiation therapy (SBRT) monotherapy for low- to intermediate-risk prostate cancer
    Eric K Oermann
    Department of Radiation Medicine, Georgetown University Hospital, Washington, DC, USA
    J Hematol Oncol 4:12. 2011
    ..We report on our early experience with CyberKnife SBRT for low- to intermediate-risk prostate cancer patients and assess the rate of inducing biochemical and clinical hypogonadism...
  21. ncbi Targeting Ku protein for sensitizing of breast cancer cells to DNA-damage
    Li Zhang
    Department of Radiation Medicine, Lombardi Cancer Center, Georgetown University, Medical Center, Washington, DC 20057, USA
    Int J Mol Med 14:153-9. 2004
    ..Thus, RNA aptamers against Ku protein show potential to sensitize MCF-7 breast carcinoma cells to DNA-damaging agents...
  22. ncbi Spatial distribution of radiation-induced double-strand breaks in plasmid DNA as resolved by atomic force microscopy
    Dalong Pang
    Department of Radiation Medicine, Georgetown University Medical Center, Washington, DC 20007, USA
    Radiat Res 164:755-65. 2005
    ....
  23. ncbi Novel HDAC inhibitors with radiosensitizing properties
    Mira Jung
    Department of Radiation Medicine, Georgetown University Medical Center, Washington, DC 20057, USA
    Radiat Res 163:488-93. 2005
    ..The data support the further investigation of these HDAC inhibitors for use as sensitizing agents with potential for clinical application...
  24. pmc ROCK inhibitor and feeder cells induce the conditional reprogramming of epithelial cells
    Xuefeng Liu
    Department of Pathology, Lombardi Comprehensive Cancer Center, Georgetown University Medical School, Washington, DC 20057, USA
    Am J Pathol 180:599-607. 2012
    ..In addition, the CRC method allows for the genetic manipulation of epithelial cells ex vivo and their subsequent evaluation in vivo in the same host...
  25. pmc Histone deacetylase inhibitor: antineoplastic agent and radiation modulator
    Zacharoula Konsoula
    Department of Radiation Medicine, Georgetown University Medical Center, Washington, DC 20057 1482, USA
    Adv Exp Med Biol 720:171-9. 2011
    ..These findings support the hypothesis that epigenetic regulation may play a crucial role in the functional recovery of normal tissues from radiation injuries...
  26. ncbi Combined external beam radiotherapy and Pd-103 brachytherapy boost improves biochemical failure free survival in patients with clinically localized prostate cancer: results of a matched pair analysis
    Anu M Singh
    Department of Radiation Medicine, Lombardi Cancer Center, Georgetown University Hospital, 3800 Reservation Rd NW, LL Bles Bldg, Washington, DC, USA
    Prostate 62:54-60. 2005
    ..Conformal dose distributions may also be achieved with brachytherapy. Therefore, biochemical control was evaluated for patients treated with combined external radiation therapy and low dose rate brachytherapy (EBRT + LDR)...
  27. ncbi Cyberknife radiosurgery for breast cancer spine metastases: a matched-pair analysis
    Gregory J Gagnon
    Department of Radiation Oncology, Georgetown University Medical Center, Washington, DC 20007 2113, USA
    Cancer 110:1796-802. 2007
    ....
  28. pmc Patient-reported outcomes following stereotactic body radiation therapy for clinically localized prostate cancer
    Onita Bhattasali
    Department of Radiation Medicine, Georgetown University Hospital, 3800 Reservoir Road, N, W, Washington, d, C 20007, USA
    Radiat Oncol 9:52. 2014
    ..Treatment-related bother may be more important to a patient than treatment-related dysfunction. This study reports on patient-reported outcomes following SBRT for clinically localized prostate cancer...
  29. doi Potency preservation following stereotactic body radiation therapy for prostate cancer
    Olusola Obayomi-Davies
    Department of Radiation Medicine, Georgetown University Hospital, 3800 Reservoir Road, NW, Washington, DC 20007, USA
    Radiat Oncol 8:256. 2013
    ..This study sought to evaluate potency preservation and sexual function following SBRT for prostate cancer...
  30. ncbi Enhancement of radiation sensitivity of human squamous carcinoma cells by histone deacetylase inhibitors
    Yin Zhang
    Department of Radiation Medicine, Georgetown University School of Medicine, Washington, DC 20057, USA
    Radiat Res 161:667-74. 2004
    ..Taken together, these results implicate G(1) arrest and inhibition of DNA synthesis in the mechanisms underlying radiation sensitization by trichostatin A and support the use of HDAC inhibitors for targeting radioresistant cancers...
  31. ncbi RAF antisense oligonucleotide as a tumor radiosensitizer
    Usha Kasid
    Department of Radiation Medicine, Lombardi Cancer Center, Georgetown University Medical Center, Washington, DC 20007, USA
    Oncogene 22:5876-84. 2003
    ..Here, we review the importance of targeting RAF-1 signaling in cancer therapy and the preclinical and clinical experiences with a liposomal formulation of a nuclease-sensitive, ends-modified antisense RAF oligonucleotide...
  32. pmc CyberKnife for hilar lung tumors: report of clinical response and toxicity
    Keith Unger
    Department of Radiation Medicine, Georgetown University Hospital, Washington, DC, USA
    J Hematol Oncol 3:39. 2010
    ..To report clinical efficacy and toxicity of fractionated CyberKnife radiosurgery for the treatment of hilar lung tumors...
  33. ncbi A pilot study of intensity modulated radiation therapy with hypofractionated stereotactic body radiation therapy (SBRT) boost in the treatment of intermediate- to high-risk prostate cancer
    Eric K Oermann
    Department of Radiation Medicine, Georgetown University Hospital, Washington, DC, USA
    Technol Cancer Res Treat 9:453-62. 2010
    ..Early results are encouraging with biochemical response and acceptable toxicity. These data provide a basis for the design of a phase II clinical trial...
  34. ncbi DNA transitions induced by binding of PARP-1 to cruciform structures in supercoiled plasmids
    Sergey Chasovskikh
    Department of Radiation Medicine, Georgetown University Medical Center, Washington, DC 20057, USA
    Cytometry A 68:21-7. 2005
    ..Previously, we have shown that PARP-1 also binds to the hairpin structures in DNA models. The mechanism underlying these interactions remains to be defined...
  35. ncbi Gene therapy for prostate cancer by targeting poly(ADP-ribose) polymerase
    Irina Trofimova
    Department of Radiation Medicine, Georgetown University Medical Center, Washington, DC 20007, USA
    Cancer Res 62:6879-83. 2002
    ..These results provide proof-of-principle for a novel therapeutic strategy for the treatment of prostate cancer...
  36. pmc Human fibroblasts for large-scale "omics" investigations of ATM gene function
    Mira Jung
    Department of Radiation Medicine, Georgetown University Medical Center, Washington, DC 20057, USA
    Adv Exp Med Biol 720:181-90. 2011
    ..We present here a summary of the derivation and characterization of cells comprising this model cell system and review applications of this model to systems analysis of ATM functions...
  37. pmc Urinary estrogen metabolites and prostate cancer risk: a pilot study
    Ourania Kosti
    Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University, Washington, District of Columbia 20057, USA
    Prostate 71:507-16. 2011
    ..The aim of this pilot study was to evaluate urinary estrogen metabolites as a biomarker of prostate cancer risk...
  38. pmc Omics-based molecular target and biomarker identification
    Zhang Zhi Hu
    Lombardi Cancer Center, Georgetown University, Washington, DC, USA
    Methods Mol Biol 719:547-71. 2011
    ..We describe a downstream workflow and procedures for functional analysis that focus on biological pathways, from which molecular targets can be derived and proposed for experimental validation...
  39. doi Analysis of LC-MS data for characterizing the metabolic changes in response to radiation
    Rency S Varghese
    Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC, USA
    J Proteome Res 9:2786-93. 2010
    ..A pathway analysis is performed following identification of the metabolites represented by the selected peaks. The results indicate an ATM regulated induction of major pathways in response to radiation treatment...
  40. ncbi Pharmacokinetics, toxicity, and efficacy of ends-modified raf antisense oligodeoxyribonucleotide encapsulated in a novel cationic liposome
    Prafulla C Gokhale
    Department of Radiation Medicine, Lombardi Cancer Center, Georgetown University Medical Center, Washington, DC 20057, USA
    Clin Cancer Res 8:3611-21. 2002
    ..LErafAON treatment caused inhibition of Raf-1 protein expression in normal and tumor tissues in these mice (>50%, versus controls). These data have formed a basis of the clinical Phase I studies of LErafAON for cancer treatment...
  41. doi Use and evaluation of a CD-ROM-based decision aid for prostate cancer treatment decisions
    Kathryn L Taylor
    Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC 20007, USA
    Behav Med 36:130-40. 2010
    ..This electronic educational tool was well-accepted by patients and may be particularly useful for patients who desire less control over their treatment decisions and who are less proactive in seeking information on their own...
  42. ncbi Transcriptional repression by binding of poly(ADP-ribose) polymerase to promoter sequences
    Viatcheslav A Soldatenkov
    Department of Radiation Medicine, Georgetown University Medical Center, Washington, DC 20007, USA
    J Biol Chem 277:665-70. 2002
    ..These data provide support for PARP protein as a potent regulator of transcription including down-regulation of its own promoter...
  43. ncbi Poly(ADP-ribose) polymerase turnover alterations do not contribute to PARP overexpression in Ewing's sarcoma cells
    Robert E Newman
    Laboratory of Experimental Carcinogenesis, Department of Radiation Medicine, Georgetown University Medical Center, Washington, DC 20007, USA
    Oncol Rep 9:529-32. 2002
    ..These data conclusively demonstrate that PARP turnover is not a determinant of either the elevated PARP content or the radiation response of EWS cells...
  44. ncbi Chemistry and biology of mercaptoacetamides as novel histone deacetylase inhibitors
    Bin Chen
    Department of Medicinal Chemistry and Pharmacognosy, University of Illinois at Chicago, 833 South Wood Street, Chicago, IL 60612, USA
    Bioorg Med Chem Lett 15:1389-92. 2005
    ..Their ability to inhibit HDAC activity and their effects on cancer cell growth were investigated. Some compounds exhibit better HDAC inhibitory activity than SAHA...
  45. ncbi Elevated frequency of ATM gene missense mutations in breast cancer relative to ethnically matched controls
    Steve S Sommer
    Department of Molecular Genetics, City of Hope National Medical Center, Duarte, CA 91010, USA
    Cancer Genet Cytogenet 134:25-32. 2002
    ..Cohort-specific structural changes are significantly more prevalent in the breast cancer patients. The data are compatible with certain missense mutations in ATM predisposing to breast cancer...
  46. ncbi ATM missense mutations are frequent in patients with breast cancer
    Steve S Sommer
    Department of Molecular Genetics, City of Hope National Medical Center, Duarte, CA 91010 3000, USA
    Cancer Genet Cytogenet 145:115-20. 2003
    ..0; 90% CI=1.01-4.15]. Cohort-specific missense variants displayed an odds ratio of 4.0 (90% CI=1.37-13.5). It is estimated that the attributable risk of mutations in the ATM gene is 13% in this cohort of women with breast cancer...
  47. ncbi Absence of somatic ATM missense mutations in 58 mammary carcinomas
    Jinong Feng
    Department of Molecular Genetics, City of Hope National Medical Center, Duarte, CA 91010, USA
    Cancer Genet Cytogenet 145:179-82. 2003
    ..73). If germline ATM missense mutations predispose to breast cancer, the unmasking of a recessive missense allele by LOH does not seem to be a critical step in breast neoplasia...